Theravance Biopharma, Inc. (TBPH) SEC Filing 10-Q Quarterly report for the period ending Friday, March 31, 2017

Exhibit 99.1

Script used in the previously announced Theravance Biopharma, Inc. conference call held May 9, 2017

***

Theravance Biopharma

1Q 2017 Financial Results Conference Call

May 9, 2017 2:00 p.m. PT/5:00 p.m. ET

Alex Dobbin, Head of Investor Relations

Good afternoon, everyone, and thank you for joining our first quarter 2017 financial results conference call and webcast. With me on the call today are Rick Winningham, Chief Executive Officer; Renee Gala, Chief Financial Officer; and Brett Haumann, Chief Medical Officer. Following our prepared remarks, we will open the call for questions. A copy of the press release and the slides accompanying this call can be downloaded from our website, or you can call investor relations at 650-808-4045 and we’ll be happy to assist you.

Before we get started, we would like to remind you that this conference call will contain forward-looking statements which involve certain risks and uncertainties including statements about our product pipeline, expected benefits of our products, the anticipated timing of trial results and regulatory filings, and expected financial results.

Information concerning factors that could cause results to differ materially from our forward-looking statements are described further in the Company’s filings made with the Securities and Exchange Commission.